Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CKS1B | P61024 | 1/20 | 0.31 |
| ▸ | SKP1 | P63208 | 1/20 | 0.31 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30361899 | 1.00 | ACVR1 (0.37) | ACVR1S1PR1PTGS2TSHRCKS1B | |
| SCHEMBL30362051 | 1.00 | ACVR1 (0.37) | ACVR1S1PR1PTGS2TSHRCKS1B | |
| SCHEMBL30362058 | 0.84 | S1PR1 (0.40) | ACVR1S1PR1PTGS2CKS1BSKP1 | |
| SCHEMBL26135194 | 0.83 | EGFR (0.41) | ACVR1PTGS2TSHR | |
| SCHEMBL26104352 | 0.83 | EGFR (0.41) | ACVR1PTGS2TSHR | |
| SCHEMBL26134025 | 0.83 | EGFR (0.41) | ACVR1PTGS2TSHR | |
| SCHEMBL30361987 | 0.82 | S1PR1 (0.44) | ACVR1S1PR1PTGS2AKT1AKT2 | |
| SCHEMBL30361895 | 0.82 | PDE10A (0.40) | S1PR1PTGS2 | |
| SCHEMBL30361897 | 0.81 | PTGS2 (0.38) | S1PR1PTGS2FAAH | |
| SCHEMBL30361821 | 0.80 | CSNK1D (0.33) | S1PR1PTGS2AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023076849-A1 | INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ORIC PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |